Full IPO calendar & reports HERE.  In order of largest IPO first:

 

(1) Based in Stamford, CT, Synchrony Financial (SYF) scheduled a $3.06 billion IPO on the NYSE with a market capitalization of $20.3 billion at a price range midpoint of $24 for Thursday, July 31, 2014.

SYF is one of the premier consumer financial services companies in the United States. It's the old GE Capital.

 

(2) Based in Somerset, NJ, Catalent (CTLT) scheduled a $871 million IPO on the NYSE with a market capitalization of $2.4 billion at a price range midpoint of $20.50 for Thursday, July 31, 2014.

CTLT is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.

 

(3) Based in Jerusalem, Israel, Mobileye N.V. (MBLY) scheduled a $500 million IPO on the NYSE with a market capitalization of $3.8 billion at a price range midpoint of $18 for Friday, August 1, 2014.

MBLY is the global leader in the design and development of software and related technologies for camera-based Advanced Driver Assistance Systems (“ADAS”).

 

(4) Based in London, United Kingdom, VTTI Energy Partners LP  (VTTI) scheduled a $350 million IPO on the NYSE, with a market capitalization of $402 million at a price range midpoint of $20 for Friday, August 1, 2014.

VTTI is a fee-based, growth-oriented limited partnership formed in April 2014 by VTTI, one of the world’s largest independent energy terminaling businesses, to own, operate, develop and acquire refined petroleum product and crude oil terminaling and related energy infrastructure assets on a global scale.

 

(5) Based in Aberdeen, United Kingdom,Transocean Partners (RIGP) scheduled a $350 million IPO on the NYSE with a market capitalization of $827 million at a price range midpoint of $20 for Thursday, July 31, 2014.

RIGP is a growth-oriented limited liability company recently formed by Transocean,one of the world’s largest offshore drilling contractors, to own, operate and acquire modern, technologically advanced offshore drilling rigs.

 

(6) Based in Houston, TX, Westlake Chemical Partners LP (WLKP) scheduled a $225 million IPO on the NYSE with a market capitalization of $508 milliion at a price range midpoint of $20 for Wednesday, July 30, 2014.

WLKP is a Delaware limited partnership recently formed by Westlake to operate, acquire and develop ethylene production facilities and related assets.

 

(7) Based in Weston, FL, FCB Financial Holdings (FCB) scheduled a $223 million IPO on the NYSE with a market capitalization of $1.02 billion at a price range midpoint of $25.50 for Friday, August 1, 2014.

 

(8) Based in Oakbrook Terrace, IL, SIRVA (SRVA) scheduled a $186 million IPO on the Nasdaq with a market capitalization of $632 million at a price range midpoint of $16 for Friday, August 1, 2014.

SRVA is a moving/relocation company.

 

(9) Based in North Billerica, MA, Lantheus Holdings (LNTH) scheduled a $125 million IPO on the Nasdaq with a market capitalization of $370 million at a price range midpoint of $13.50 for Wednesday, July 30, 2014.

LNTH is a global leader in developing, manufacturing, selling and distributing innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases.

 

(10) Based in Draper, UT, Health Equity (HQY) scheduled a $100 million IPO on the Nasdaq with a market capitalization of $546 million at a price range midpoint of $11 for Thursday, July 31, 2014.

HQY is a leader and an innovator in the high growth category of technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions.

 

(11) Based in Or Yehuda, Israel, Vascular Biogenics (VBLX) scheduled a $76 million IPO on the Nasdaq with a market capitalization of $259 million at a price range midpoint of $14 for Thursday, July 31, 2014.

VBLX is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases.

 

(12) Based in Menlo Park, CA, Avalanche Biotechnologies (AAVL) scheduled a $76 million IPO on the Nasdaq with a market capitalization of $292 million at a price range midpoint of $14 for Thursday, July 31, 2014.

AAVL is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

 

(13) Based in Zug, Switzerland, Auris Medical Holding AG (EARS) scheduled a $76 million IPO on the Nasdaq with a market capitalization of $283 million at a price range midpoint of $11 for Friday, August 1, 2014.

EARS is a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders.

 

(14) Based in Petach Tikva, Israel, Macrocure (MCUR) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $264 million at a price range midpoint of $14 for Thursday, July 31, 2014.

MCUR is a regenerative medicine company focused on developing, manufacturing and commercializing novel cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds.

 

(15) Based in Fremont, CA, Zosano Pharma (ZSAN) scheduled a $70 million IPO on the Nasdaq with a market capitalization of $134 million at a price range midpoint of $11 for $134 million for the week of July 28th.

ZSAN is a clinical stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver its proprietary formulations of existing drugs through the skin for the treatment of a variety of indications.

 

(16) Based in South San Francisco, CA, Tobira Therapeutics (TBRA) scheduled a $60 million IPO on the Nasdaq with a market capitalization of $143 million at a price range midpoint of $13 for Thursday, July 31, 2014.

TBRA is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV, fibrosis and inflammation.

 

(17) Based in Stamford, CT, Loxo Oncology (LOXO) scheduled a $57 million IPO on the Nasdaq with a market capitalization of $196 million at a price range midpoint of $13 for Friday, August 1, 2014.

LOXO develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations.

 

(18) Based in New Haven, CT, Marinus Pharmaceuticals (MRNS) scheduled a $52 million IPO on the Nasdaq with a market capitalization of $159 million at a price range midpoint of $13 for Thursday, July 31, 2014.

MRNS is a clinical stage biopharmaceutical company focused on developing and commercializing innovative neuropsychiatric therapeutics.

 

(19) Based in Tel Aviv, Israel, Bio Blast Pharma Ltd. (ORPN) scheduled a $40 million IPO on the Nasdaq with a market capitalization of $172 million at a price range midpoint of $172 for Friday, Aug. 1, 2014.

ORPN is a development-stage biopharmaceutical company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases.

 

(20) Based in Yonker, NY, ContraFect (CFRXU) scheduled a $20 million IPO on the Nasdaq with a market capitalization of $96 million at a price range midpoint of $5.50 for Tuesday, July 29, 2014.

CFRXU is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.